Irish Court Rejects Perrigo's Bid To Quash $1.92B Tax Bill

Law360 (November 4, 2020, 8:12 PM EST) -- Pharmaceutical maker Perrigo failed Wednesday in its bid to get Ireland's High Court to dismiss a €1.64 billion ($1.92 billion) tax assessment that the Irish company has derided as an abuse of power by the national tax authorities.

The bill stems from the 2013 sale of Perrigo's 50% stake in Tysabri, a drug used to treat multiple sclerosis and Crohn's disease, to U.S.-based Biogen Inc. Perrigo claimed the November 2018 assessment by the Revenue Commissioners, Ireland's tax authority, violated its rights.

But the High Court said the company hadn't made a case for undercutting the assessment, which arose from what the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!